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Abstract
Background: Travel to mountain areas is popular. However, the effects of acute exposure to moderate altitude on the
cardiovascular system and metabolism are largely unknown.
Objectives: To investigate the effects of acute exposure to moderate altitude on vascular function, metabolism and
systemic inflammation.
Methods: In 51 healthy male subjects with a mean (SD) age of 26.9 (9.3) years, oxygen saturation, blood pressure, heart rate,
arterial stiffness, lipid profiles, low density lipoprotein (LDL) particle size, insulin resistance (HOMA-index), highly-sensitive C-
reactive protein and pro-inflammatory cytokines were measured at 490 m (Zurich) and during two days at 2590 m, (Davos
Jakobshorn, Switzerland) in randomized order. The largest differences in outcomes between the two altitudes are reported.
Results: Mean (SD) oxygen saturation was significantly lower at 2590 m, 91.0 (2.0)%, compared to 490 m, 96.0 (1.0)%,
p,0.001. Mean blood pressure (mean difference +4.8 mmHg, p,0.001) and heart rate (mean difference +3.3 bpm,
p,0.001) were significantly higher at 2590 m, compared to 490 m, but this was not associated with increased arterial
stiffness. At 2590 m, lipid profiles improved (median difference triglycerides 20.14 mmol/l, p = 0.012, HDL +0.08 mmol/l,
p,0.001, total cholesterol/HDL-ratio 20.25, p = 0.001), LDL particle size increased (median difference +0.45 nm, p = 0.048)
and hsCRP decreased (median difference 20.18 mg/l, p = 0.024) compared to 490 m. No significant change in pro-
inflammatory cytokines or insulin resistance was observed upon ascent to 2590 m.
Conclusions: Short-term stay at moderate altitude is associated with increased blood pressure and heart rate likely due to
augmented sympathetic activity. Exposure to moderate altitude improves the lipid profile and systemic inflammation, but
seems to have no significant effect on glucose metabolism.
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Introduction
Travel to mountain areas for leisure activities or a professional
reason has become increasingly popular for lowland residents. It
has been estimated that several million people in the US and
Europe travel to moderate altitude each year, many of which have
known or unknown arterial hypertension, diabetes mellitus,
disturbances in lipid metabolism and cardiovascular disease.
Understanding the interactions between hypoxia, measures of
cardiovascular function and metabolism is an important require-
ment for counselling persons travelling to altitude. However, the
acute effects of moderate altitude exposure on measures of
cardiovascular function and metabolism are still incompletely
defined. This is because very few studies, most of which included a
small number of subjects and differed regarding the duration of
altitude exposure, looked at the effects of moderate altitude on
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measures of cardiovascular function, glucose and lipid metabolism.
In addition, the studied populations differed considerably, with
some studies including healthy men and women and others
including patients with several comorbidities, thus resulting in
contradictory findings do not allow to draw final conclusions [1–
6]. However, hypobaric hypoxia has previously been shown to be
associated with increased sympathetic activity which in turn may
have a substantial effect not only on blood pressure but also on
glucose and lipid metabolism [7–9].
We have addressed this uncertainty by performing a randomized,
controlled, cross-over trial investigating the effects of acute exposure
tomoderate altitude onmeasures of cardiovascular function, glucose
and lipid metabolism as well as on measures of systemic
inflammation in healthy male adults. We hypothesized that acute
exposure to moderate altitude leads to hypoxemia associated with
worsening of cardiovascular function, glucose and lipid metabolism
as well as with an increase in systemic inflammation.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
This was a randomized cross-over trial evaluating the acute
effects of hypobaric hypoxia at moderate altitude on measures of
vascular function, metabolism, sleep, and psychomotor perfor-
mance in healthy men. The trial was conducted between June and
October 2010 and comprised a baseline study in Zurich and an
altitude sojourn of 4 days in Davos (Switzerland). Assessments
were performed at 3 elevations: 1) Zurich, 490 m, barometric
pressure (PB) 958.59 hPa; 2) Davos Wolfgang, 1630 m, PB 839.93
hPa) Davos Jakobshorn, 2590 m (PB 749.27 hPa). Assessments of
vascular function and metabolism were performed at 490 m as
baseline and daily during two following days at 2590 m. The trials’
outcomes on sleep, vigilance and psychomotor performance will
be reported elsewhere. The trial was performed and analysed
according to CONSORT guidelines (www.consort-statement.org).
Participants and ethical approval
Subjects were eligible if they were healthy males, between 18
and 70 years old, and living below 800m. Subjects with a body
mass index (BMI) ,18 or .30 kg/m2, any medical condition
requiring treatment, regular use of medications, alcohol, nicotine
or drugs, a history of sleep disorders or previous altitude related
illness at altitude ,3000 m were excluded.
The study was approved by the local Zurich ethics committee
(KEK ZH 2010–0054/1) and registered (NCT01130948). Written
informed consent was obtained from all participants.
The experiments were conducted according to the standards of
the Declaration of Helsinki.
Interventions
Participants were randomized to 4 groups with permuted
sequences of altitude exposure according to a balanced block
design: group A) 490 m/1630 m/1630 m/2590 m/2590 m, B)
490 m/2590 m/2590 m/1630 m/1630 m, C) 1630 m/1630 m/
2590 m/2590 m/490 m, D) 2590 m/2590 m/1630 m/1630 m/
490 m (figure 1). The participants travelled by train from Zurich
to Davos and in 30 minutes by cable car from Davos train station
(1630 m) to Davos Jakobshorn (2590 m).
Assessments
All examinations on cardiovascular and metabolic outcomes
reported in this manuscript have only been collected at 490 m and
2590 m. On study days all participants were asked to abstain from
sporting activities and received standard meals with an energy
content of 600–800 kcal consisting of approximately 50%
carbohydrates, 30% protein and 20% fat three times daily (at all
altitudes). All daytime examinations were performed after waking
in the morning after an overnight fast. All clinical measurements
were performed by trained physicians. Laboratory and statistical
analyses were performed by personnel blinded to randomisation,
the altitude and clinical data.
Blood pressure, heart rate and digital volume pulse
analysis. Blood pressure and heart rate were measured in
triplicate in the morning with a standard digital automatic monitor
(M6, Omron Healthcare Company, Kyoto, Japan) in supine
position after a period of rest of 5 minutes. The average of the
three blood pressure measurements was used for further analysis.
Arterial stiffness was estimated by digital volume pulse (DVP)
analysis as previously described and validated (Pulse TraceH PCA
2, CareFusion, Rolle, Switzerland) [10]. The device collects 6
representative pulse waveforms with a pulse interval close to the
average pulse interval. From the averaged pulse waveforms the
arterial stiffness index (SI) is derived, which is defined as height
divided by the time from the systolic to diastolic inflection point.
Two measurements were performed and the average of the two
measurements was used for final analysis.
Blood markers of systemic inflammation, insulin
resistance and lipid profiles. Blood was drawn in the
morning between 6–7 am and blood samples were stored at
280uC for later analysis. Measurements of highly-sensitive C-
reactive protein (hsCRP), IL-6, IL-10 and tumor necrosis factor
(TNF)-a, lipid profiles and insulin resistance by homeostatic model
assessment (HOMA) were performed from plasma samples as
previously described [11,12].
The Dade Behring BN method (particle-enhanced immunone-
phelometry, measuring range 0.18–1150 mg/L) was used to
measure hsCRP as previously described and validated [13].
IL-6, IL-10 and TNF-a were measured by ELISA with
commercially available kits (BMS213HS and BMS223HS, Bender
MedSystems GmbH, Vienna, Austria). The lower limit of
detection for IL-6, IL-10 and TNF-a were 0.03 pg/ml, 0.05 pg/
ml and 0.13 pg/ml respectively. The intra- and interassay
coefficients of variation were 4.9 % and 6.0 %, respectively for
IL-6 and 6.8 % and 7.5 % for IL-10, and 8.5 % and 9.8 % for
TNF-a. All blood markers of systemic inflammation were
measured in duplicate and in the same batch.
Gradient gel electrophoresis was performed at 10–14uC in 2–
16% polyacrylamide gradient gels. Gels were subjected to
electrophoresis 24 h at 125 V in tris borate puffer (ph 8.3) as
previously described [14,15]. Gels were fixed and stained for lipids
in a solution containing oil red O in 60% ethanol at 55uC. Gels
were placed on light source and photographed using a Lumines-
cent Image Analyzer (LAS-3000, Fujifilm). Migration distance for
each absorbance peak was determined and the molecular diameter
corresponding to each peak was calculated from a calibration
curve generated from the migration distance of size standards with
known diameter including carboxylated latex beads (Duke
Scientific, Palo Alto, CA, USA), thyroglobulin, and apoferritin
(HMW Std., Pharmacia, Piscataway NJ, USA) having molecular
diameters of 38, 17, and 12.2 nm, respectively, and lipoprotein
calibrators of previously determined particle size. The coefficient
of variation between measurements was 1.3%. Low density
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lipoprotein subfraction distribution (LDL-I, -IIA, -IIB, -IIIA, -IIIB,
-IVA, and IVB) is expressed as percentage of total LDL [15].
Outcomes and sample size
Primary outcomes were blood pressure and arterial stiffness
index. Additional outcomes were heart rate, blood markers of
systemic inflammation, insulin resistance and lipid profiles. To
detect clinically relevant differences in mean blood pressure of
5.0 mmHg (SD 6.0) and in stiffness index of 1.0 m/s (SD 1.2) with
a two-sided significance level of 0.05 and a power of 80%, a
sample size of 46 subjects was necessary [10,16,17].
Data analysis
All values are presented as mean (SD) or median (quartiles) as
appropriate. Statistical analyses were performed with Statistica
V6.0 (StatSoft, Tulsa, Oklahoma, USA).
Changes in the measured variables from Zurich (490 m) to
Davos Jakobshorn (2590 m) were assessed by ANOVA for
repeated measurements with Fisher post hoc analysis or non-
parametric Friedman ANOVA and Wilcoxon post hoc analysis as
appropriate. Statistical significance was assumed at a probability of
p,0.05 applying a Bonferroni correction.
Results
Subjects
51 male subjects were eligible for entry, were randomised and
completed the study protocol (figure 1). The mean age of the study
population was 26.9 (9.3) years and the mean body mass index
was 23.1 (2.5) kg/m2.
Effects of moderate altitude on oxygen saturation and
vascular function
As expected oxygen saturation was significantly lower on both
days at 2590 m (table 1) and blood pressure and heart rate were
significantly higher compared to 490 m (table 1). Arterial stiffness
Figure 1. Study flow.
doi:10.1371/journal.pone.0070081.g001
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as assessed by DVP analysis did not significantly change upon
ascent to moderate altitude (table 1).
Effects of moderate altitude on lipid profiles
There was no significant change in total and LDL cholesterol
upon ascent to 2590 m (table 2). However, HDL cholesterol was
significantly higher and total cholesterol/HDL ratio as well as
triglyceride levels were significantly lower at 2590 m compared to
490 m (table 2, figure 2). LDL cholesterol particle diameter was
significantly greater on both days at 2590 m compared to 490 m
(table 2, figure 3). There was an increase of LDL subfraction I upon
ascent to 2590 m (table 2).
Effects of moderate altitude on systemic inflammation
HsCRP decreased significantly upon ascent to 2590 m (table 2,
figure 4), however, no statistically significant changes in IL-6, IL-
10 and TNF-a were observed (table 2).
Effects of moderate altitude on glucose metabolism
There was no significant change in blood glucose, insulin and
insulin resistance as assessed by HOMA upon ascent to 2590 m
(table 2).
Discussion
This is the first randomised controlled study to investigate the
effects of acute exposure to moderate altitude on vascular function,
glucose and lipid metabolism as well as on systemic inflammation in
healthy males. We found that exposure to moderate altitude was
associatedwith significant increases in blood pressure and heart rate,
possibly due to augmented sympathetic activity. Short-term stay at
moderate altitude was associated with improvements in lipid profiles
and a decrease in systemic inflammation. However, moderate
altitude did not have a significant effect on glucose metabolism.
In the current study ascent to 2590 m, an altitude commonly
visited by families during skiing and hiking vacations, resulted in
hypoxemia in all subjects (mean SpO2 91%). Exposure to mild
hypobaric hypoxia was associated with considerable increases in
both blood pressure and heart rate (table 1). This is in contrast to a
small study including 10 normotensive subjects in which no effect
of acute exposure to moderate altitude (2572 m) on blood pressure
was found [1]. A possible explanation for this discrepancy is the
small sample size of the study by D’Este and colleagues [1] (10
normotensive and 13 hypertensive subjects) as well as differences
regarding the population studied. However, the findings of studies
investigating the effects of high and very high altitude in healthy
subjects suggest that acute exposure to more severe hypobaric
hypoxia is associated with increased sympathetic activity resulting
in elevated heart rate and blood pressure [18–21]. The observed
acute effects of moderate altitude on blood pressure and heart rate
may be even more pronounced in patients with arterial
hypertension [19], and may possibly add to the peak of risk for
myocardial infarction observed within the first two days of
vacation in patients with coronary artery disease [22,23].
Despite the observed increase in blood pressure and heart rate,
arterial stiffness as estimated by digital volume pulse analysis
derived stiffness index (SI) did not change significantly at moderate
altitude in the current study. This is concordant with the report of
Rhodes et al. [24] who found an unchanged SI in 17 subjects after
ascent to 3450 m. Thus it seems that acute exposure to moderate
and high altitude has no immediate effect on arterial stiffness.
Upon ascent to moderate altitude lipid profiles improved
significantly in our study, i.e. a decrease in triglycerides and total
cholesterol/HDL ratio as well as an increase in HDL was observed
(table 2). Moreover, at altitude the average LDL particle size
increased, which was related to a significant increase in LDL
subfraction I particles (figure 3). These changes are consistent with
a reduction of atherogenicity and are thus thought to reduce
cardiovascular risk [25,26]. Low-density lipoprotein (LDL) size is
an important predictor of cardiovascular events and progression of
coronary artery disease, and the predominance of small, dense
LDL has been accepted as an emerging cardiovascular risk factor
in various populations. Since the therapeutic modulation of
distinct LDL subspecies, as seen in our trial, seems to result in
reduced cardiovascular events [8,26,27], our findings suggest that
mild hypobaric hypoxia may be beneficial to modulate atheroge-
nicity. To our knowledge there is no other data on the acute effects
of moderate altitude on lipid profiles and LDL particle size in
healthy humans. The results from studies investigating the effects
of high and very high altitude on blood lipids are contradictory
[28–30], possibly due to small sample sizes, heterogeneity in the
study populations and differences related to the level of altitude.
However, the findings of a study investigating the effects of a
hiking vacation at moderate altitude (1700 m) in patients with the
metabolic syndrome suggest that activity at moderate altitude is
associated with improvement of lipid profiles after 3 weeks [2,4].
These effects may be sustained, as it has been found in
epidemiological studies that HDL levels increase when living at
higher altitude [31].
We observed no significant effect of acute exposure to moderate
altitude on various measures of glucose metabolism in healthy
humans. This is in contrast to a Chinese study which reported
improvement of glucose tolerance as assessed by oral glucose
tolerance testing (OGTT) after 3 days at 2400 m in 9 untrained
subjects [3]. This discrepancy may be explained by the small
sample size, the different method used to assess glucose
metabolism, the different ethnicity and other differences regarding
the participant characteristics in the study by Lee et al [3].
Table 1. Effects of moderate altitude on oxygen saturation and vascular function.
Variable 490 m n=51 2590 m (day1) p vs 490m* n=51 2590 m (day2) p vs 490 m* n=51
Oxygen saturation (%) 96.0 (1.0) 91.0 (2.0) ,0.001 92.0 (2.0) ,0.001
Systolic BP (mmHg) 119.5 (8.6) 123.5 (7.6) ,0.001 125.0 (6.8) ,0.001
Diastolic BP (mmHg) 70.8 (5.1) 74.6 (5.7) ,0.001 75.9 (5.5) ,0.001
Mean BP (mmHg) 87.5 (5.5) 90.9 (5.7) ,0.001 92.3 (6.0) ,0.001
Heart rate (bpm) 56.7 (8.8) 60.1 (10.4) 0.004 60.1 (9.5) ,0.001
Stiffness Index (m/s) 6.2 (1.4) 6.3 (1.3) NA 6.1 (1.0) NA
Values are means (SD). BP = blood pressure. * P-values refer to post-hoc comparisons of variables with P ANOVA ,0.05. NA: P ANOVA .0.05.
doi:10.1371/journal.pone.0070081.t001
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Figure 2. Effects of moderate altitude on lipids. Black lines represent medians. Panel A shows individual high density lipoprotein (HDL) blood
levels in Zurich (490 m) and Davos Jakobshorn (2590 m). HDL was higher on both days (d1, d2) at 2590 m compared to 490 m. *p,0.001 vs 490 m.
Panel B shows individual total cholesterol/high density lipoprotein (HDL) ratios in Zurich (490 m) and Davos Jakobshorn (2590 m). Total cholesterol/
HDL ratio was lower on both days (d1, d2) at 2590 m compared to 490 m. *p,0.05 vs 490 m. Panel C shows individual triglyceride blood levels in
Zurich (490 m) and Davos Jakobshorn (2590 m). Triglycerides were lower on day 2 at 2590 m compared to 490 m. *p,0.05 vs 490 m.
doi:10.1371/journal.pone.0070081.g002
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However, the lack of an effect on HOMA in our study suggests
that there is no clinically important effect of acute exposure to
moderate altitude on insulin resistance in healthy Caucasians.
There is some evidence that severe hypobaric, hypoxic
conditions at high altitude stimulate the expression of pro-
inflammatory markers such as hsCRP and IL-6 [32–34]. In the
current study, acute exposure to moderate altitude was associated
with a significant decrease in systemic inflammation as assessed by
hsCRP, but no change in IL-6, IL-10 or TNF-a was observed. To
our knowledge there are no other data published on the effect of
moderate altitude on systemic inflammation. Our findings suggest
that acute, mild hypobaric-hypoxia has an anti-inflammatory
effect. In contrast severe hypobaric hypoxia experienced at higher
Figure 3. Effects of moderate altitude on LDL diameter.
Scatterplot showing individual median low density lipoprotein (LDL)
diameter in Zurich (490 m) and Davos Jakobshorn (2590 m) during
day 1 and day 2. Black lines represent medians. LDL diameter was larger
on both days at 2590 m compared to 490 m. *p,0.05 vs 490 m.
doi:10.1371/journal.pone.0070081.g003
Table 2. Effects of moderate altitude on metabolism and inflammation.
Variable 490 mn=51 2590 m (day 1) n=51 P vs 490m* 2590 m (day 2) n=51 P vs 490m*
Triglycerides (mmol/l) 0.75 (0.62, 0.9) 0.67 (0.52, 0.9) 0.094 0.61 (0.49, 0.9) 0.012
Total Chol (mmol/l) 3.70 (3.6, 4.4) 4.0 (3.70, 4.5) NA 4.0 (3.5, 4.5) NA
HDL Chol (mmol/l) 1.25 (1.1, 1.41) 1.3 (1.18, 1.5) ,0.001 1.33 (1.16, 1.53) ,0.001
Total Chol/HDL-Ratio 3.2 (2.7, 3.8) 3.0 (2.6, 3.7) 0.015 2.95 (2.5, 3.4) 0.001
LDL Chol (mmol/l) 2.2 (2.0, 2.8) 2.4 (2.0, 2.8) NA 2.2 (1.9, 2.6) NA
LDL particle size (nm) 26.08 (25.8, 26.5) 26.37 (26.01, 26.71) 0.008 26.53 (26.03, 26.9) 0.048
LDL I (%) 18.8 (16.3, 23.3) 22.2 (18.1, 26.3) 0.009 21.7 (19.0, 26.1) 0.022
LDL IIA (%) 14.8 (12.7, 16.3) 15.1 (13.0, 16.4) NA 15.3 (13.7, 17.1) NA
LDL IIB (%) 20.0 (18.0, 24.1) 18.9 (16.3, 22.7) NA 19.4 (16.1, 21.5) NA
LDL IIIA (%) 16.5 (14.7, 19.3) 16.2 (13.6, 17.8) NA 15.4 (13.3, 18.0) NA
LDL IIIB (%) 6.4 (5.6, 7.6) 6.0 (5.5, 7.3) NA 5.9 (5.1, 7.1) NA
LDL IVA (%) 9.5 (8.4, 10.2) 8.9 (9.8, 7.8) NA 9.0 (8.0, 10.3) NA
LDL IVB (%) 10.6 (9.3, 12.3) 10.1 (12.1, 9.1) NA 11.1 (9.4, 12.6) NA
hsCRP (mg/l) 0.44 (0.18, 0.91) 0.26 (0.17, 0.53) 0.024 0.33 (0.17, 0.5) 0.054
Interleukin-6 (pg/ml) 0.54 (0.28, 0.94) 0.40 (0.26, 0.62) NA 0.43 (0.28, 0.63) NA
Interleukin-10 (pg/ml) 0.51 (0.36,1.2) 0.56 (0.31, 1.1) NA 0.64 (0.34, 0.92) NA
TNF-a (pg/ml) 0.77(0.67, 1.0) 0.83 (0.62, 1.0) NA 0.77 (0.63, 1.04) NA
Glucose (mmol/l) 5.2 (5.0, 5.4) 5.1 (5.0, 5.4) NA 5.1 (4.9, 5.4) NA
Insulin (mU/ml) 2.0 (2.0, 2.8) 2.0 (2.0, 3.1) NA 2.0 (2.0, 2.2) NA
HOMA-Index 0.47 (0.44, 0.7) 0.46 (0.44, 0.71) NA 0.47 (0.44, 0.7) NA
Values are medians (quartiles). Chol = cholesterol; HDL = high density lipoprotein; LDL = low density lipoprotein, LDL I, IIA, IIB, IIIA, IIIB, IVA, IVB = LDL subfractions.
HsCRP = highly sensitive C-reactive protein, TNF-a= Tumor necrosis factor a. HOMA-index = Homeostatic model assessment-index = fasting insulin (mU/ml) x fasting
glucose (mmol/l)/22.5. *P-values refer to post-hoc comparisons of variables with P ANOVA ,0.05. NA: P ANOVA . 0.05.
doi:10.1371/journal.pone.0070081.t002
Figure 4. Effects of moderate altitude on C-reactive protein.
Scatterplot showing individual highly sensitive C-reactive protein
(hsCRP) blood levels in Zurich (490 m) and Davos Jakobshorn
(2590 m). Black lines represent medians. HsCRP levels were lower on
day 1 at 2590 m compared to 490 m. *p,0.05 vs 490 m.
doi:10.1371/journal.pone.0070081.g004
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altitudes seems to have a pro-inflammatory effect. The divergent
findings of previous studies regarding the effect of altitude on
hsCRP can possibly be explained by different altitude levels
(moderate vs high altitude), differences of the studied populations
(healthy vs diseased participants), the non-randomised design and
small sample size of previous studies, and differences of physical
activity levels during the study period.
Our study has some limitations; as it was designed to assess the
short-term effects of moderate altitude exposure, we do not know
whether the observed effects on the cardiovascular system, lipid
metabolism and systemic inflammation are sustained during a
longer stay at moderate altitude; a question that needs to be
addressed in future studies. As we selectively included healthy male
subjects to study the effects of moderate altitude in a large
homogeneous population, the findings of the current study should
be extrapolated with caution to females and patients with
cardiovascular or metabolic disease. Although it is conceivable
that similar effects can be expected in females and such patients,
this will need to be proven in further studies.
In conclusion, the current study has shown that a short-term
stay at moderate altitude is associated with mild hypoxemia
leading to increased blood pressure and heart rate, likely due to
augmented sympathetic activity. In contrast, exposure to moderate
altitude seems to improve the lipid profile and systemic
inflammation, however, it seems to have no relevant effect on
glucose metabolism.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
Author Contributions
Conceived and designed the experiments: MK PA RH KB. Performed the
experiments: ACS TL CL SL KS NT LA KB PG RH PA KEB MK.
Analyzed the data: ACS TL CL SL KS NT LA KB PG RH PA KEB MK.
Contributed reagents/materials/analysis tools: ACS TL CL SL KS NT LA
KB PG RH PA KEB MK. Wrote the paper: ACS TL CL SL KS NT LA
KB PG RH PA KEB MK.
References
1. D’Este D, Mantovan R, Martino A, D’Este F, Artusi L, et al. (1991) The
behavior of the arterial pressure at rest and under exertion in normotensive and
hypertensive subjects exposed to acute hypoxia at a median altitude. GItal
Cardiol 21: 643–649.
2. Greie S, Humpeler E, Gunga HC, Koralewski E, Klingler A, et al. (2006)
Improvement of metabolic syndrome markers through altitude specific hiking
vacations. J Endocrinol Invest 29: 497–504.
3. Lee WC, Chen JJ, Ho HY, Hou CW, Liang MP, et al. (2003) Short-term
altitude mountain living improves glycemic control. High Alt Med Biol 4: 81–91.
4. Schobersberger W, Schmid P, Lechleitner M, Von Duvillard SP, Hoertnagl H,
et al. (2003) Austrian moderate altitude study 2000 (AMAS 2000). The effects of
moderate altitude (1700m) on cardiovascular and metabolic variables in patients
with metabolic syndrome. Eur J Appl Physiol 88: 506–514.
5. Schobersberger W, Leichtfried V, Mueck-Weymann M, Humpeler E (2010)
Austrian moderate altitude studies (AMAS): benefits of exposure to moderate
altitudes (1500–2500m). Sleep Breath 14: 201–207.
6. Temte JL (1996) Elevation of serum cholesterol at high altitude and its
relationship to hematocrit. Wilderness Environ Med 7: 216–224.
7. Kelly KR, Williamson DL, Fealy CE, Kriz DA, Krishnan RK, et al. (2010)
Acute altitude-induced hypoxia suppresses plasma glucose and leptin in healthy
humans. Metabolism 59: 200–205.
8. Licht CM, de Geus EJ, Penninx BW (2013) Dysregulation of the autonomic
nervous system predicts the development of the metabolic syndrome. J Clin
Endocrinol Metab jc.2012–3104 [pii];10.1210/jc.2012–3104 [doi].
9. Vats P, Ray K, Majumadar D, Amitabh, Joseph DA, et al. (2013) Changes in
cardiovascular functions, lipid profile, and body composition at high altitude in
two different ethnic groups. High Alt Med Biol 14: 45–52. 10.1089/
ham.2012.1071 [doi].
10. Clarenbach CF, Stoewhas AC, Van Gestel AJ, Latshang TD, Lo Cascio CM, et
al. (2012) Comparison of photoplethysmographic and arterial tonometry-derived
indices of arterial stiffness. Hypertens Res 35: 228–233.
11. Kohler M, Ayers L, Pepperell JCT, Packwood KL, Ferry B, et al. (2009) Effects
of continuous positive airway pressure on systemic inflammation in patients with
moderate to severe obstructive sleep apnoea: a randomised controlled trial.
Thoarx 64: 67–73.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–
419.
13. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, et al. (2001)
Evaluation of nine automated high-sensitivity C-reactive protein methods: implica-
tions for clinical and epidemiological applications. Part 2. Clin Chem 47: 418–425.
14. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, et al. (2010) Ezetimibe
alone or in combination with simvastatin increases small dense low-density
lipoproteins in healthy men: a randomized trial. Eur Heart J 31: 1633–1639.
15. Krauss RM, Burke DJ (1982) Identification of multiple subclasses of plasma low
density lipoproteins in normal humans. J Lipid Res 23: 97–104.
16. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, et al. (1990) Blood
pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in
blood pressure: overview of randomised drug trials in their epidemiological
context. Lancet 335: 827–838.
17. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, et al. (1990) Blood pressure,
stroke, and coronary heart disease. Part 1, Prolonged differences in blood
pressure: prospective observational studies corrected for the regression dilution
bias. Lancet 335: 765–774.
18. Bernardi L, Passino C, Spadacini G, Calciati A, Robergs R, et al. (1998)
Cardiovascular autonomic modulation and activity of carotid baroreceptors at
altitude. Clinical Science 95: 565–573.
19. Kanstrup IL, Poulsen TD, Hansen JM, Andersen LI, Bestle MH, et al. (1999)
Blood pressure and plasma catecholamines in acute and prolonged hypoxia:
effects of local hypothermia. J Appl Physiol 87: 2053–2058.
20. Vogel JA, Harris CW (1967) Cardiopulmonary responses of resting man during
early exposure to high altitude. J Appl Physiol 22: 1124–1128.
21. Wolfel EE, Selland MA, Mazzeo RS, Reeves JT (1994) Systemic hypertension at
4,300m is related to sympathoadrenal activity. J Appl Physiol 76: 1643–1650.
22. Kop WJ, Vingerhoets A, Kruithof GJ, Gottdiener JS (2003) Risk factors for
myocardial infarction during vacation travel. Psychosom Med 65: 396–401.
23. Wyss CA, Koepfli P, Fretz G, Seebauer M, Schirlo C, et al. (2003) Influence of
altitude exposure on coronary flow reserve. Circulation 108: 1202–1207.
24. Rhodes HL, Chesterman K, Chan CW, Collins P, Kewley E, et al. (2011)
Systemic blood pressure, arterial stiffness and pulse waveform analysis at
altitude. J R Army Med Corps 157: 110–113.
25. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, et al. (1988)
Low-density lipoprotein subclass patterns and risk of myocardial infarction.
JAMA 260: 1917–1921.
26. National Cholesterol Education Program (NCEP) expert panel on detection,
evaluation, and treatment of high blood cholesterol in adults. (2002) Third
report of the National Cholesterol Education Program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol in adults (adult
treatment panel III) final report. Circulation 106: 3143–3421.
27. Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular
prevention. Eur J Intern Med 17: 77–80.
28. Barnholt KE, Hoffman AR, Rock PB, Muza SR, Fulco CS, et al. (2006)
Endocrine responses to acute and chronic high-altitude exposure (4300 meters):
modulating effects of caloric restriction. Am J Physiol Endocrinol Metab 290:
1078–1088.
29. Ferezou J, Richalet JP, Coste T, Rathat C (1988) Changes in plasma lipids and
lipoprotein cholesterol during a high altitude mountaineering expedition
(4800m). Eur J Appl Physiol Occup Physiol 57: 740–745.
30. Smith JD, Cianflone K, Martin J, Poirier P, Broderick TL, et al. (2011) Plasma
adipokine and hormone changes in moutaineers on ascent to 5300 meters.
Wilderness Environ Med 22: 107–114.
31. Dominguez Coello S, Cabrera De Leon A, Bosa Ojeda F, Perez Mendez LI,
Diaz Gonzalez L, et al. (2000) High density lipoprotein cholesterol increases with
living altitude. Int J Epidemiol 29: 65–70.
32. Bailey DM, Kleger GR, Holzgraefe M, Ballmer PE, Bartsch P (2004)
Pathophysiological significance of peroxidative stress, neuronal damage, and
membrane premeability in acute mountain sickness. J Appl Physiol 96: 1459–
1463.
33. Hartmann G, Tschop M, Fischer R, Bidlingmaier C, Riepl R, et al. (2000) High
altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and
C-reactive protein. Cytokine 12: 246–252.
34. Mazzeo RS, Donovan D, Fleshner M, Butterfield GE, Zamudio S, et al. (2001)
Interleukin-6 response to exercise and high-altitude exposure: influence of alpha-
adrenergic blockade. J Appl Physiol 91: 2143–2149.
Effects of Acute Exposure to Moderate Altitude
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e70081
